BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Did You See This Week’s Top Stem Cell News?
Did You See This Week's Top Stem Cell News?

Did You See This Week’s Top Stem Cell News?

February 22, 2016 By Cade Hildreth (CEO) Leave a Comment

We’ve released new content on stem cell and cord blood markets that we are excited to share with you. Enjoy!

Discover class-defining bioproduction tools.

Q&A Interview with Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics

Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, 3D technology platform to develop cell therapies for a broad range of diseases. Pluristem Therapeutics specializes in placental-derived “PLX” cells, which are now being explored for applications that include critical limb ischemia (CLI), acute radiation syndrome (ARS), incomplete bone marrow engraftment, and more.

BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents

Rooster DevServices

BioTime, Inc. and Asterias Biotherapeutics have entered into a “patent Cross-License Agreement for pluripotent stem cell-derived cell therapies and other potential uses that will provide the companies with the freedom to leverage a patent estate covering the therapeutic uses of pluripotent stem cell technology in their respective areas of focus.”

The Golden Age of BioPrinting, Tissue Engineering, & BioFabrication 

bitbio

This is a guest post from RoosterBio, an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation. A “Golden Age” is defined as a period of time in a field where “great tasks are accomplished.” As described by author Jon Rowley, we are now at the beginnings of the Golden Age of BioFabrication.

How Many Billions Are Spent Annually on Stem Cell Research? (The NIH Alone Spends $1.5B/Year)
Within the U.S., the National Institutes of Health (NIH) will invest an estimated $1.495 billion into stem cell research projects in 2016, spanning a wide range of fields from cell biology to electrical engineering. This is an increase from $1.391 billion in (actual) stem cell spending by the NIH in 2014 and $1.429 billion in (estimated) spending in 2015.

Pluristyx

Transforming Stem Cell Research and Therapies – Minerva Discovers Naïve Stem Cell Growth Factor

Minerva Biotechnologies announces a “major breakthrough for stem cell research and therapies – a simple method of inducing naïve state pluripotency in human stem cells.” While induced pluripotent stem cell (iPSC) techniques can reprogram an adult cell to a stem cell-like state, Minerva has discovered a “primitive growth factor, NME7-AB, that continues this reprogramming to an even earlier, embryonic-like point called the ‘naïve’ state.”

iPSC-derived cardiomyocte therapy

Mesenchymal Stem Cell (MSC) Company Cynata Therapeutics Reports Nearly $1 Million R&D Tax Incentive Refund

Cynata Therapeutics announced that it is receiving a R&D Tax Incentive refund of nearly $1 million for the 2014/2015 financial year. This major cash influx will assist the company with the upcoming clinical trial involving its Cymerus™ mesenchymal stem cell (MSC) product, CYP-001. Cynata’s Cymerus™ MSCs are derived from a single donation from a single donor, using induced pluripotent stem cells (iPSCs) as the source tissue.

NIH’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

Pluristem Therapeutics marks its first entry into the defense area. NIAID, a part of the U.S. National Institutes of Health (NIH), will initiate studies in large animals to evaluate dosing for Pluristem’s PLX-R18 as a medical countermeasure in the treatment of the hematologic components of Acute Radiation Syndrome (ARS).

Product: Branding Package – Communicating Your Message into the Stem Cell Marketplace

In the past couple years, BioInformant has completely taken over the stem cell space. We dominate Google search for a massive number of stem cell terms, have the fastest growing stem cell account on Twitter, are a Top Influencer for Stem Cells on LinkedIn, sponsor stem cell industry conferences, release hundreds of articles on stem cell market news per year, and are a media expert for stem cell topics — most recently interviewed by the Wall Street Journal, Los Angeles Business Journal, and Xconomy. Unless you’re getting the same level of attention, check this out!


Want to be better informed than your competition? Get future stem cell industry updates.

 

About Us

BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.

Click here to view our global strategic reports for the stem cell and cord blood industry.

Rate this post

Filed Under: Stem Cells Tagged With: cynata therapeutics, market news, Pluristem Therapeutics, press release, RoosterBio, stem cells

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.